Recent Developments in Cancer Pharmacotherapy and Personalized Medicine

Abstract

Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating continuous advancements in therapeutic strategies to improve patient outcomes. Traditional cancer treatments, including chemotherapy, radiation therapy, and surgery, have significantly contributed to cancer management; however, their effectiveness is often limited by non-specific targeting, treatment resistance, and adverse side effects. Recent developments in cancer pharmacotherapy have transformed the oncology landscape through the introduction of targeted therapies, immunotherapies, gene-based treatments, and precision medicine approaches that offer more effective and individualized treatment options. Advances in molecular biology, genomics, proteomics, and bioinformatics have enhanced the understanding of cancer pathogenesis and enabled the identification of specific genetic mutations, molecular biomarkers, and signaling pathways involved in tumor development and progression. These discoveries have facilitated the development of targeted pharmacological agents that selectively inhibit cancer-promoting mechanisms while minimizing damage to healthy tissues. In addition, immunotherapeutic strategies such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines have demonstrated remarkable success in treating various malignancies by enhancing the body's immune response against tumor cells.